

Remarks

Claims 1-29 are pending.


In response to the Office Action, applicant hereby elects the claims of Group III, as identified in the Office Action, with traverse. Accordingly, applicant elects claims 1-9, 12, 17-19, and 22-27.

Applicant traverses the restriction requirement because all of the groups of claims identified by the Examiner relate to the treatment of neurogenic inflammation pain, and thus, are directed to a single invention. Accordingly, the restriction requirement is improper, and applicant submits that claims 1-29 are directed to a single invention.

In conclusion, applicant requests that all of the pending claims (i.e., claims 1-29) be examined in the above-identified application. Applicant requests early and favorable action in the above-identified application

Respectfully submitted,

Date: OCTOBER 14, 2003



Frank J. Uxa  
Attorney for Applicant  
Registration No. 25,612  
4 Venture, Suite 300  
Irvine, California 92618  
(949) 450-1750  
(949) 450-1764 Facsimile